Department of Neurology

Vascular Neurology Research

Current Studies

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Principle Investigator: Sajjad Mueed, MD

Enrollment Status: Active

Study Objectives: The Primary Specific Aim of this randomized, double-blind, multicenter clinical trial is to determine whether copidogreg 75 mg/day by mouth after a loading dose of 600 mg is effective in improving survival free from ischemic vascular events at 90 days when subjects are randomized within 12 hours of time last known free of new symptoms in patients receiving aspirin 50-325 mg/day.

Several secondary analyses will be performed, including as treated analysis and evaluations of the impact of therapy on risk of the composite of major ischemic vascular events or major hemorrhage and on risk of major systemic or intracranial hemorrhage separately. Additional tertiary/exploratory analyses will include evaluation of the impact of therapy on:

  1. ischemic stroke
  2. hemorrhagic stroke
  3. all-cause death
  4. new handicap/disability

The impact of therapy on the composite outcome will also be evaluated in specific subject groups (e.g. African American, those previously taking aspirin, those with index TIA vs minor ischemic stroke).